Omnicell Q2 Revenue Plunges 12.5%, Net Income Halved
Ticker: OMCL · Form: 10-Q · Filed: Aug 6, 2025 · CIK: 926326
| Field | Detail |
|---|---|
| Company | Omnicell, Inc. (OMCL) |
| Form Type | 10-Q |
| Filed Date | Aug 6, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Healthcare Technology, Q2 Earnings, Revenue Decline, Net Income Drop, Financial Performance
Related Tickers: OMCL
TL;DR
OMCL's Q2 numbers are a disaster, showing a deep cut in product sales and profits; time to sell.
AI Summary
OMNICELL, INC. reported a significant decline in revenue and net income for the second quarter and first six months of 2025. Total revenue for Q2 2025 was $245.2 million, a decrease from $280.1 million in Q2 2024. Product revenue specifically fell from $170.1 million in Q2 2024 to $135.2 million in Q2 2025, representing a 20.5% drop. Service revenue also decreased slightly from $110.0 million to $110.0 million in the same period. For the six months ended June 30, 2025, total revenue was $490.4 million, down from $558.2 million in the prior year. The company's net income for Q2 2025 was $10.3 million, a substantial decrease from $25.1 million in Q2 2024. Diluted earnings per share followed suit, dropping from $0.57 in Q2 2024 to $0.23 in Q2 2025. The filing indicates a challenging operational environment, with no specific new business changes highlighted, but the financial performance suggests headwinds in product sales. Key risks include continued revenue contraction and the impact on profitability, as evidenced by the 59% decline in net income. The strategic outlook appears focused on navigating these revenue pressures, though specific forward-looking statements are not detailed in the provided excerpt.
Why It Matters
OMCL's significant revenue and net income declines signal a challenging period for the company, impacting investor confidence and potentially future growth prospects. The 20.5% drop in product revenue suggests competitive pressures or reduced demand for its core offerings, which could affect employees through potential restructuring or hiring freezes. Customers might see slower innovation or less aggressive pricing if the company tightens its belt. In the broader market, this performance could indicate a slowdown in healthcare technology spending, potentially affecting other players in the automated medication management space.
Risk Assessment
Risk Level: high — The risk level is high due to the substantial financial deterioration. Revenue for Q2 2025 decreased by 12.5% to $245.2 million from $280.1 million in Q2 2024, and net income plummeted by 59% from $25.1 million to $10.3 million in the same period. This significant decline across key financial metrics indicates severe operational challenges and potential market share loss.
Analyst Insight
Investors should consider reducing their exposure to OMCL given the sharp declines in revenue and net income. The significant drop in product sales suggests fundamental business challenges that may persist, making the stock a high-risk investment in the short to medium term.
Financial Highlights
- revenue
- $245.2M
- net Income
- $10.3M
- eps
- $0.23
- revenue Growth
- -12.5%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product Revenue | $135.2M | -20.5% |
| Service Revenue | $110.0M | 0.0% |
Key Numbers
- $245.2M — Q2 2025 Total Revenue (down 12.5% from Q2 2024's $280.1M)
- $135.2M — Q2 2025 Product Revenue (down 20.5% from Q2 2024's $170.1M)
- $10.3M — Q2 2025 Net Income (down 59% from Q2 2024's $25.1M)
- $0.23 — Q2 2025 Diluted EPS (down from Q2 2024's $0.57)
- $490.4M — Six-Month 2025 Total Revenue (down from $558.2M in prior year)
Key Players & Entities
- OMNICELL, INC. (company) — filer of the 10-Q
- $245.2 million (dollar_amount) — total revenue for Q2 2025
- $280.1 million (dollar_amount) — total revenue for Q2 2024
- $135.2 million (dollar_amount) — product revenue for Q2 2025
- $170.1 million (dollar_amount) — product revenue for Q2 2024
- $110.0 million (dollar_amount) — service revenue for Q2 2025 and Q2 2024
- $490.4 million (dollar_amount) — total revenue for six months ended June 30, 2025
- $558.2 million (dollar_amount) — total revenue for six months ended June 30, 2024
- $10.3 million (dollar_amount) — net income for Q2 2025
- $25.1 million (dollar_amount) — net income for Q2 2024
FAQ
What were OMNICELL, INC.'s total revenues for Q2 2025?
OMNICELL, INC.'s total revenues for the second quarter of 2025 were $245.2 million, a decrease from $280.1 million in the second quarter of 2024.
How did OMNICELL, INC.'s product revenue change in Q2 2025 compared to Q2 2024?
Product revenue for OMNICELL, INC. in Q2 2025 was $135.2 million, a significant decrease from $170.1 million in Q2 2024, representing a 20.5% decline.
What was OMNICELL, INC.'s net income for the second quarter of 2025?
OMNICELL, INC. reported a net income of $10.3 million for Q2 2025, which is a substantial drop from $25.1 million in Q2 2024.
What was the diluted earnings per share for OMNICELL, INC. in Q2 2025?
The diluted earnings per share for OMNICELL, INC. in Q2 2025 was $0.23, down from $0.57 in Q2 2024.
What were OMNICELL, INC.'s total revenues for the first six months of 2025?
For the six months ended June 30, 2025, OMNICELL, INC.'s total revenues were $490.4 million, compared to $558.2 million for the same period in 2024.
What are the key risks highlighted by OMNICELL, INC.'s Q2 2025 performance?
The key risks highlighted by OMNICELL, INC.'s Q2 2025 performance include continued revenue contraction, particularly the 20.5% decline in product revenue, and the significant impact on profitability, evidenced by the 59% decrease in net income.
How does OMNICELL, INC.'s Q2 2025 performance impact investors?
OMNICELL, INC.'s Q2 2025 performance, with its sharp declines in revenue and net income, suggests a challenging outlook that could negatively impact investor returns and confidence, warranting a re-evaluation of investment positions.
Did OMNICELL, INC. report any significant business changes in this 10-Q?
The provided excerpt from the 10-Q filing for OMNICELL, INC. does not detail any specific new business changes, but the financial results clearly indicate a challenging operational environment.
What is the trend in OMNICELL, INC.'s service revenue?
OMNICELL, INC.'s service revenue remained flat at $110.0 million for both Q2 2025 and Q2 2024, indicating stability in this segment despite product revenue declines.
What does the 10-Q filing indicate about OMNICELL, INC.'s strategic outlook?
While the 10-Q filing does not explicitly detail OMNICELL, INC.'s strategic outlook, the significant financial declines suggest the company will likely focus on addressing revenue pressures and improving profitability in the near future.
Risk Factors
- Revenue Contraction [high — financial]: Total revenue declined 12.5% in Q2 2025 to $245.2 million from $280.1 million in Q2 2024. Product revenue saw a steeper drop of 20.5%. This ongoing revenue contraction poses a significant risk to future profitability.
- Declining Profitability [high — financial]: Net income for Q2 2025 was $10.3 million, a 59% decrease from $25.1 million in Q2 2024. Diluted EPS fell from $0.57 to $0.23, reflecting the impact of lower revenues and potentially increased costs or operational inefficiencies.
- Challenging Operational Environment [medium — operational]: The company is operating in a challenging environment, as indicated by the broad decline in revenue across key segments. While no specific new business changes are highlighted, the performance suggests underlying operational pressures impacting sales.
Industry Context
Omnicell operates in the healthcare technology sector, specifically focusing on medication management and pharmacy automation solutions. The industry is characterized by a need for efficiency, safety, and cost reduction in healthcare settings. Competitors often offer integrated solutions for inventory management, dispensing, and analytics.
Regulatory Implications
As a healthcare technology provider, Omnicell is subject to regulations concerning data privacy (like HIPAA in the US) and the security of medical devices. Compliance with these regulations is crucial for maintaining customer trust and avoiding penalties, though no specific new regulatory issues were highlighted in this filing.
What Investors Should Do
- Monitor product sales trends closely.
- Analyze cost management strategies.
- Evaluate the stability of service revenue.
Glossary
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the source of the financial data and analysis presented.)
- Diluted EPS
- Earnings per share (EPS) that reflects the potential dilution from all dilutive securities, such as stock options and convertible bonds. (Indicates the company's profitability on a per-share basis, accounting for all potential shares outstanding.)
- Product Revenue
- Revenue generated from the sale of physical goods or tangible products. (A key segment of Omnicell's business that experienced a significant decline, impacting overall financial performance.)
- Service Revenue
- Revenue generated from providing services, such as maintenance, support, or consulting. (Another key segment of Omnicell's business, which remained flat year-over-year in Q2 2025.)
Year-Over-Year Comparison
Compared to the prior year's filing, Omnicell has experienced a notable downturn in financial performance. Total revenue for the six months ended June 30, 2025, is down from $558.2 million to $490.4 million. This revenue contraction is mirrored in the second quarter, with total revenue falling 12.5% and product revenue dropping 20.5%. Consequently, net income has seen a sharp decline of 59% in Q2 2025, and diluted EPS has decreased significantly, indicating a more challenging operating environment than previously reported.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 6, 2025 regarding OMNICELL, INC. (OMCL).